Connect with us

COVID-19

Conservative MPs say gov’t agency ‘lied’ about sweetheart deals for Canada’s COVID travel app

Published

1 year ago

5 minute read

From LifeSiteNews

By Anthony Murdoch

MP Kelly Block said at a House of Commons government operations committee meeting that there ‘was misconduct’ and ‘very bizarre’ lapses concerning an $11.1 million contract awarded to a supplier.

Conservative Party of Canada (CPC) MPs accused the Canada Border Services Agency (CBSA) of lying to Parliament over sweetheart contracting approvals concerning the federal government’s $54 million controversial COVID-era ArriveCAN travel app.

As per Blacklock’s Reporter, CPC MP Kelly Block said recently at a House of Commons government operations committee meeting that there “was misconduct” from the CBSA along with “very bizarre” lapses concerning an $11.1 million contract awarded to supplier GC Strategies Inc.

“We have I think been misled and perhaps even lied to when it comes to the individuals knowing who in fact chose GC Strategies,” Block said.

The CBSA was tasked with building the ArriveCAN app.

The House of Commons Standing Committee on Government Operations and Estimates (OGGO) is investigating how various companies such as Dalian, Coaradix, and GC Strategies received millions in taxpayer dollars to develop the contentious quarantine-tracking ArriveCAN app.

Two weeks ago, LifeSiteNews reported that an investigation into ArriveCAN by Alexander Jeglic, the government’s procurement ombudsman, revealed that three-quarters of the contractors who were paid to work on ArriveCAN did not do anything in building the scandal-plagued app.

The investigation’s report singles out GC Strategies, saying the two-man company did not prove that its list of subcontractors was qualified to work on the app.

The procurement ombudsman’s report also found “numerous examples” in which GC Strategies “had simply copied and pasted” required work experience that was listed by the government for its contractors.

The report also noted that it was unusual the government used criteria for the app’s tender that were “overly restrictive and favoured” GC Strategies, which won the contract bid despite the fact no other bids were submitted.

Jeglic testified to the committee that it was “highly unusual” GC Strategies got the bid to make ArriveCAN.

“It is impossible to demonstrate fairness if you do not have records demonstrating how you evaluated all of the bids,” he said, noting that open bidding is vital in being “fair, open and transparent.”

CPC MP Larry Block said it was time to “deal with the elephant in the room.”

“The elephant in the room is the expansion of outsourcing. Last year alone, $14.6 billion was spent on federal outsourcing,” he said.

Thus far, only two federal executives who worked on the ArriveCAN app have been suspended. The Royal Canadian Mounted Police are investigating the contractors who worked on the program.

Canadians were told ArriveCAN was supposed to have cost only $80,000, but the number quickly ballooned to $54 million.

As for the app itself, it was riddled with tech glitches along with privacy concerns from users.

ArriveCAN was introduced in April 2020 by the Trudeau government and made mandatory in November 2020. The app was used by the federal government to track the COVID jab status of those entering the country and enforce quarantines when deemed necessary.

When the app was mandated, all travelers entering Canada had to use it to submit their travel and contact information as well as any COVID vaccination details before crossing the border or boarding a flight.

Canadian Auditor General Karen Hogan announced an investigation of the ArriveCAN app in November 2022 after the House of Commons voted 173-149 for a full audit of the controversial app.

Last year, LifeSiteNews reported on two tech entrepreneurs testifying before the committee that during the development of the ArriveCAN travel app they saw firsthand how federal managers engaged in “extortion,” “corruption,” and “ghost contracting,” all at the expense of taxpayers.

Related Topics:

Todayville is a digital media and technology company. We profile unique stories and events in our community. Register and promote your community event for free.

Follow Author

More from this author
Economy / 3 mins ago

US strategy to broker peace in Congo and Rwanda – backed by rare earth minerals deal

Crime / 20 mins ago

Mexican Cartels smuggling crude oil in Texas, Southwest border

International / 1 hour ago

Pentagon Salivates Over ‘Expensive’ Weapons While China Races Into Future With Iron Grip Over Cheap Drone Tech

COVID-19

Tulsi Gabbard says US funded ‘gain-of-function’ research at Wuhan lab at heart of COVID ‘leak’

Published on May 3, 2025

By

From LifeSiteNews

By Conservative Treehouse

The director of National Intelligence revealed gain-of-function ties to US funding, which could indicate that the US helped bankroll the supposed COVID lab leak.

In this segment of a remarkable interview by Megyn Kelly, Director of National Intelligence Tulsi Gabbard discusses the current Intelligence Community (IC) research into the origin of the SARS-CoV-2 pandemic (aka, COVID-19).

Gabbard talks about the U.S. government funding of “gain-of-function” research, which is a soft sounding phrase to describe the weaponization of biological agents.

Gabbard notes the gain-of-function research taking place in the Wuhan lab was coordinated and funded by the United States government, and the IC is close to making a direct link between the research and the release of the COVID-19 virus.

Additionally, Gabbard explains the concern of other biolabs around the world and then gets very close to the line of admitting the IC itself is politically weaponized (which it is but would be stunning to admit).

 

Continue Reading

COVID-19

Study finds Pfizer COVID vaccine poses 37% greater mortality risk than Moderna

Published on May 1, 2025

By

From LifeSiteNews

By Nicolas Hulscher, MPH

A study of 1.47 million Florida adults by MIT’s Retsef Levi and Surgeon General Joseph Ladapo finds significantly higher all-cause mortality after Pfizer vaccination compared to Moderna

A new study of 1.47 million Florida adults by MIT’s Retsef Levi and Surgeon General Joseph Ladapo finds significantly higher all-cause, cardiovascular, and COVID-19 mortality after Pfizer vaccination.

The study titled “Twelve-Month All-Cause Mortality after Initial COVID-19 Vaccination with Pfizer-BioNTech or mRNA-1273 among Adults Living in Florida” was just uploaded to the MedRxiv preprint server. This study was headed by MIT Professor Retsef Levi, with Florida Surgeon General Dr. Joseph Ladapo serving as senior author:

Study Overview

  • Population: 1,470,100 noninstitutionalized Florida adults (735,050 Pfizer recipients and 735,050 Moderna recipients).
  • Intervention: Two doses of either:
    • BNT162b2 (Pfizer-BioNTech)
    • mRNA-1273 (Moderna)
  • Follow-up Duration: 12 months after second dose.
  • Comparison: Head-to-head between Pfizer vs. Moderna recipients.
  • Main Outcomes:
    • All-cause mortality
    • Cardiovascular mortality
    • COVID-19 mortality
    • Non-COVID-19 mortality

All-cause mortality

Pfizer recipients had a significantly higher 12-month all-cause death rate than Moderna recipients — about 37% higher risk.

  • Pfizer Risk: 847.2 deaths per 100,000 people
  • Moderna Risk: 617.9 deaths per 100,000 people
  • Risk Difference:
    ➔ +229.2 deaths per 100,000 (Pfizer excess)
  • Risk Ratio (RR):
    ➔ 1.37 (i.e., 37% higher mortality risk with Pfizer)
  • Odds Ratio (Adjusted):
    ➔ 1.384 (95% CI: 1.331–1.439)

Cardiovascular mortality

Pfizer recipients had a 53% higher risk of dying from cardiovascular causes compared to Moderna recipients.

  • Pfizer Risk: 248.7 deaths per 100,000 people
  • Moderna Risk: 162.4 deaths per 100,000 people
  • Risk Difference:
    ➔ +86.3 deaths per 100,000 (Pfizer excess)
  • Risk Ratio (RR):
    ➔ 1.53 (i.e., 53% higher cardiovascular mortality risk)
  • Odds Ratio (Adjusted):
    ➔ 1.540 (95% CI: 1.431–1.657)

COVID-19 mortality

Pfizer recipients had nearly double the risk of COVID-19 death compared to Moderna recipients.

  • Pfizer Risk: 55.5 deaths per 100,000 people
  • Moderna Risk: 29.5 deaths per 100,000 people
  • Risk Difference:
    ➔ +26.0 deaths per 100,000 (Pfizer excess)
  • Risk Ratio (RR):
    ➔ 1.88 (i.e., 88% higher COVID-19 mortality risk)
  • Odds Ratio (Adjusted):
    ➔ 1.882 (95% CI: 1.596–2.220)

Non-COVID-19 mortality

Pfizer recipients faced a 35% higher risk of dying from non-COVID causes compared to Moderna recipients.

  • Pfizer Risk: 791.6 deaths per 100,000 people
  • Moderna Risk: 588.4 deaths per 100,000 people
  • Risk Difference:
    ➔ +203.3 deaths per 100,000 (Pfizer excess)
  • Risk Ratio (RR):
    ➔ 1.35 (i.e., 35% higher non-COVID mortality risk)
  • Odds Ratio (Adjusted):
    ➔ 1.356 (95% CI: 1.303–1.412)

Biological explanations

The findings of this study are surprising, given that Moderna’s mRNA-1273 vaccine contains approximately three times more mRNA (100 µg) than Pfizer’s BNT162b2 vaccine (30 µg). This suggests that the higher mortality observed among Pfizer recipients could potentially be related to higher levels of DNA contamination — an issue that has been consistently reported worldwide:

The paper hypothesizes differences between Pfizer and Moderna may be due to:

  • Different lipid nanoparticle compositions
  • Differences in manufacturing, biodistribution, or storage conditions

Final conclusion

Florida adults who received Pfizer’s BNT162b2 vaccine had higher 12-month risks of all-cause, cardiovascular, COVID-19, and non-COVID-19 mortality compared to Moderna’s mRNA-1273 vaccine recipients.

Unfortunately, without an unvaccinated group, the study cannot determine the absolute increase in mortality risk attributable to mRNA vaccination itself. However, based on the mountain of existing evidence, it is likely that an unvaccinated cohort would have experienced much lower mortality risks. It’s also important to remember that Moderna mRNA injections are still dangerous.

As the authors conclude:

These findings are suggestive of differential non-specific effects of the BNT162b2 and mRNA-1273 COVID-19 vaccines, and potential concerning adverse effects on all-cause and cardiovascular mortality. They underscore the need to evaluate vaccines using clinical endpoints that extend beyond their targeted diseases.

Nicolas Hulscher, MPH

Epidemiologist and Foundation Administrator, McCullough Foundation

www.mcculloughfnd.org

Please consider following both the McCullough Foundation and my personal accounton X (formerly Twitter) for further content.

Reprinted with permission from Focal Points.

Continue Reading

Trending

X